Corona Remedies
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Management at CORONA Remedies Limited has articulated a clear growth strategy, emphasizing recent acquisitions and capacity expansions that enhance its competitive position in key therapeutic areas. The acquisition of Wokadine® and brands from Bayer and Dr. Reddy’s is expected to bolster market share, particularly in chronic and sub-chronic segments, which are crucial for driving revenue growth. However, the company faces execution risks associated with entering new therapeutic areas and regulatory challenges in international markets. Vista's financial outlook reflects a cautious stance, anticipating moderating revenue growth and ongoing margin pressures due to rising costs. Despite these challenges, the company's focus on improving MR productivity and expanding its prescriber base is expected to support long-term growth. The Indian pharmaceutical sector's favorable dynamics, including improving pricing power and a strong pipeline of innovative products, provide a supportive backdrop for CORONA's strategy. Over the next 12-24 months, key opportunities include new product launches and strategic acquisitions, while watchpoints include potential supply chain disruptions and volatile energy prices that could impact margins
Why We Like This Stock
- Recent acquisitions enhance market presence and support revenue growth in key therapeutic areas
- Capacity expansions at the Bhayla facility are expected to drive future growth
- Management's focus on chronic and sub-chronic segments aligns with market trends and offers significant growth potential
Things To Watch Out For
- Execution risks associated with entering new therapeutic areas could hinder growth
- Ongoing margin pressures from rising costs and regulatory challenges may impact profitability
- External uncertainties, such as volatile energy prices and supply chain disruptions, pose risks to financial stability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,014 | 1,196 | 1,403 | 1,506 | 1,669 |
| Profit Before Tax (Cr.) | 119 | 200 | 259 | 283 | 312 |
| PBT Margin | 11.7% | 16.7% | 1846.8% | 18.8% | 18.7% |
| Net Profit (Cr.) | 97 | 154 | 199 | 216 | 239 |
| Earnings Per Share | 15.8 | 25.1 | 32.6 | 35.4 | 39.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.